Current Headlines

  1. Ametek Announces Two Acquisitions
    2/5/2016

    Brookfield Engineering Broadens AMETEK’s Laboratory Instrumentation Platform ESP/SurgeX Expands AMETEK’s Power Protection Platform

  2. Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars Education Initiative
    2/4/2016

    The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States – issued the following statement about the Biosimilars hearing before the House Energy and Commerce, Subcommittee on Health and the launch of a new biosimilars education initiative.

  3. Beike Biotechnology To Supply 11 Hospitals With Cell Therapy
    2/4/2016

    Beike Biotechnology, the Shenzhen local government, and various medical institutions attended a ceremony in late 2015 to mark their successful combined efforts to provide integrative, personalized cell therapy in 2016.

  4. Invetech And Celyad To Collaborate On C-Cure Production
    2/3/2016

    Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Celyad SA, (CYAD.BR) ("Celyad"), a biopharmaceutical company focused on identification and development of specialized cell-based therapies with product candidates in oncology and cardiology, today announced that they have entered into an agreement under which Invetech will develop and supply manufacturing systems to support production needs for C-Cure®, Celyad's most advanced product candidate based on the cardiopoiesis technology platform.

  5. Experts To Meet In Boston To Discuss Biggest Challenges In The Analytical And Clinical Phases Of Biosimilar Drug Development
    2/3/2016

    IQPC has made several recent additions to the speaking faculty of the Biosimilars Clinical Studies & Analytical Similarity Summit.

  6. Morphotek Announces Collaboration With Mayo Clinic On Phase II Trial
    2/3/2016

    Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida in a clinical study in patients with folate receptor alpha (FRA) positive, triple-negative breast cancer (TNBC).

  7. Epigenetics Market Growth Forecast At 13.64% CAGR To 2020
    2/3/2016

    Global epigenetics market is expected to reach USD 890.0 million by 2020 growing at a CAGR of 13.64% between 2015 and 2020 with market growth majorly driven by the high prevalence of cancer, increasing R & D funding and increasing intensity of genomic research activities.

  8. Telesta Therapeutics Receives Complete Response Letter From FDA
    2/2/2016

    Telesta Therapeutics Inc. (TSX:TST) (PNK:BNHLF) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to Telesta's Biologics License Application (BLA) for MCNA1. In this letter, the FDA communicated that an additional Phase 3 clinical trial for MCNA would be necessary to adequately establish MCNA's efficacy and safety.

  9. Nimbus Therapeutics Granted Fast Track Designation For NASH Treatment
    2/2/2016

    Nimbus Therapeutics, a biotechnology company focused on harnessing the power of computational chemistry to design breakthrough drugs for serious, underserved human diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for NDI-010976, Nimbus’ liver-targeted allosteric inhibitor of acetyl-CoA carboxylase (ACC), for the treatment of NASH (non-alcoholic steatohepatitis).

  10. Teva And AbCellera Enter Into Agreement To Discover Rare mAbs
    2/2/2016

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.